According to Bloomberg, Qiagen NV (QGEN) and BioMerieux are exploring a potential combination

  • November 3, 2021


Date Announced11/03/2021Source Bloomberg
TypeNews Report

Molecular testing firm Qiagen NV (QGEN) and French rival BioMerieux are exploring a potential combination that would unite two of Europe’s biggest medical diagnostics providers, people with knowledge of the matter said.

Previously on February 9, 2021, Qiagen NV (QGEN) was approached by Quidel Corp. (QDEL)

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.